Boston Scientific Corporation (BSX) recently reported $5.2 billion in revenue and an EPS of $0.80, exceeding analysts' expectations, but the company is grappling with stock volatility after management lowered its full-year 2026 guidance. The stock has fallen 7.8% over the past month, prompting concerns from notable investor Jim Cramer regarding its performance. While BSX maintains a 'Strong Buy' consensus rating, analysts have adjusted earnings expectations, reflecting a slightly less bullish outlook despite a projected 10.5% year-over-year increase in EPS.
“Boston Scientific · has returned · past month · -7.8%”
“Boston Scientific · is expected to post earnings · current quarter · $0.84 per share”
“Boston Scientific · has consensus earnings estimate change · current quarter · -3.2%”
“Boston Scientific · reported revenues · last reported quarter · $5.2 billion”
“Boston Scientific · has year-over-year change in revenues · last reported quarter · +11.6%”
“Boston Scientific · reported EPS · last reported quarter · $0.8”
“Boston Scientific · surpassed consensus EPS estimates · last four quarters · three times”
“Boston Scientific · topped consensus revenue estimates · last four quarters · each time”
“Boston Scientific Corporation (BSX) · has a market cap of · $86.9 billion · true”
“BSX · has underperformed · State Street Healthcare Select Sector SPDR ETF (XLV) · true”
“BSX's revenue · rose · 11.6% · from the prior year's quarter to $5.2 billion”
“BSX's adjusted EPS · amounted to · $0.80 · and surpassed estimates”
